Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

Patent metadata

Field	Value
Publication number	US-11013740-B2
Application number	US-201916299310-A
Country	US
Kind code	B2
Filing date	Mar 12, 2019
Priority date	Jun 1, 2015
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.

First claim

We claim:

1. A method for restoring a loss of intra-epidermal nerve fiber (IENF) in a subject, comprising administering to the subject an effective amount of a histone deacetylase 6 selective inhibitor;
wherein the loss of intra-epidermal nerve fiber is the result of administering cisplatin to the subject.

2. The method of claim 1 , wherein the administration of the histone deacetylase 6 selective inhibitor to the subject occurs during or after administering cisplatin.

3. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is compound 001:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin.

5. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is administered before administering cisplatin.

Assignees

• Regenacy Pharmaceuticals Llc
• Univ Texas

Inventors

• Kavelaars Annemieke
• Heijnen Cobi J
• Krukowski Karen
• Jarpe Matthew B

Classifications

• A61K33/24

  Heavy metals; Compounds thereof · CPC title

• A61K33/243

  Platinum; Compounds thereof · CPC title

• A61K31/505 Primary

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title